ADMA Biologics and some executives face a securities fraud lawsuit alleging they misled investors by inflating revenue through excess shipments of their product ASCENIV and hiding a related-party distribution deal. The truth surfaced after a report in March 2026 revealed unsold inventory was driving reported growth, causing the stock price to drop sharply. Investors who bought ADMA stock between August 2024 and March 2026 and suffered losses may be eligible to join the lawsuit. The deadline to seek lead plaintiff status is August 10, 2026, and investors are encouraged to contact Block & Leviton for more information or to participate.
ADMA Biologics experienced challenges earlier this year but showed recovery in Q2 with ASCENIV revenue up 24% and a strong 69% gross margin. The company lowered its long-term targets but improved receivable collections have boosted investor confidenc...
Berger Montague law firm is investigating ADMA Biologics' Board of Directors for potential breaches of fiduciary duty, focusing on allegations that the company engaged in channel-stuffing to inflate revenue despite declining demand for its main produ...
